Hydrogenology
Hydrogenology editorial study record

Effect of hydrogen inhalation on cardiovascular and interstitial components of pulmonary hypertension in rats

Kuropatkina TA, Gufranov K, Sychev FY, et al. · Pulmonologiya. 2024;34(1):19–30.

PreclinicalInhaled H₂Published 2024
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled monocrotaline pulmonary-hypertension rat study

Research topic

Respiratory health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Male Wistar rats with monocrotaline-induced pulmonary hypertension.

Sample

Outcome table reports control n=7, monocrotaline control n=6 and monocrotaline plus H₂ n=6.

Duration

Continuous exposure for 21 days.

Intervention

Continuous exposure to nominal 4% H₂ in air for 21 days after monocrotaline administration.

Hydrogen form

H₂ mixed with room air — H₂ alone from the generator, not Brown's gas.

H₂ specification

Outlet concentration was 4.1±0.3% H₂. The methods list 150 mL/min H₂ and 4 mL/min air; those printed flows cannot mathematically produce 4% H₂, so Hydrogenology does not reconcile them.

H₂ flow

150 mL/min H₂ is printed in the methods, but it is internally inconsistent with the printed air flow and measured 4.1% concentration.

O₂ delivered with H₂

No supplemental O₂ was co-delivered; room air was the diluent. The full article does not report an absolute O₂ flow.

Comparator

Monocrotaline plus room air and solvent-only control groups.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Right-ventricular pressure and hypertrophy, lung histology, mast cells, fibrosis and TGF-β immunostaining.

Reported result

Hydrogen did not change the principal pulmonary-hypertension cardiovascular measures: right-ventricular systolic pressure was 57±9 versus 58±7 mmHg. Mast-cell counts and several inflammatory/fibrotic lung findings were lower with hydrogen.

Results-extraction completeness

The complete free publisher full article, methods, tables, positive and null results were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical model. No benefit was found for the principal cardiovascular manifestations of pulmonary hypertension. The article contains an unresolved flow inconsistency: 150 mL/min H₂ plus 4 mL/min air cannot yield the stated 4.1% H₂.

Applies directly to

Monocrotaline pulmonary-hypertension model in rats only.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

OpenAlex ID: W4392132150 · DOI: 10.18093/0869-0189-2024-34-1-19-30

Publisher access

Open-access publisher article under CC BY-NC 4.0.

Extraction basis

Pulmonologiya full article; full-text extraction checked 8 August 2026.

Record revision

2026-08-10